Friederike Liesche-Starnecker

Dr. Friederike Liesche-Starnecker

Technical University Munich, School of Medicine, Institute of Pathology, Department of Neuropathology
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
APAnne-Katrin Pröbstel
Anne-Katrin Pröbstel
XZXiaoyuan Zhou
Xiaoyuan Zhou
RBRyan Baumann
Ryan Baumann
SWSven Wischnewski
Sven Wischnewski
MKMichael Kutza
Michael Kutza
SBSergio Baranzini
Sergio Baranzini
IgA + cells act as a systemic mediator between the gut and the central nervous system during active multiple sclerosis.

1 April 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
HNHans Helmut Niller
Hans Helmut Niller
KAKlemens Angstwurm
Klemens Angstwurm
DRDennis Rubbenstroth
Dennis Rubbenstroth
KSKore Schlottau
Kore Schlottau
AEArnt Ebinger
Arnt Ebinger
BSBarbara Schmidt
Barbara Schmidt

24 April 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NBNatalie Bergmann
Natalie Bergmann
CDClaire Delbridge
Claire Delbridge
JGJens Gempt
Jens Gempt
AFAnnette Feuchtinger
Annette Feuchtinger
AWAxel Walch
Axel Walch
JSJürgen Schlegel
Jürgen Schlegel
Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumor in adults. Despite extensive therapy the prognosis for GBM patients remains poor and the extraordinary therapy resistance has been attributed to intertumoral heterogeneity of glioblastoma. Different prognostic relevant GBM tumor subtypes have been identified based on their molecular profile. This approach, however, neglects the heterogeneity within individual tumors, that is, the intratumoral heterogeneity. Here, we detected the regional immunoreactivity by immunohistochemistry and immunofluorescence using nine different markers on resected GBM specimens (IDH wildtype, WHO grade IV). We found repetitive expression profiles, that could be classified into clusters. These clusters could then be assigned to five pathophysiologically relevant groups that reflect the previously described subclasses of GBM, including mesenchymal, classical, and proneural subtype. Our data indicate the presence of tumor differentiations and tumor subclasses that occur within individual tumors, and might therefore contribute to develop adapted, individual-based therapies.

30 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
AHAdrien Holzgreve
Adrien Holzgreve
ABAnnamaria Biczok
Annamaria Biczok
VRViktoria C. Ruf
Viktoria C. Ruf
FLFriederike Liesche-Starnecker
Friederike Liesche-Starnecker
Katja SteigerKatja Steiger
Katja Steiger
Bogdana SuchorskaBogdana Suchorska
Bogdana Suchorska
Aim: The aim of the current study was to enlighten the evolution of prostate-specific membrane antigen (PSMA) expression in glioblastoma between initial diagnosis and recurrence in order to provide preliminary insight for further clinical investigations into innovative PSMA-directed treatment concepts in neuro-oncology.Methods: Patients who underwent resection for de-novo glioblastoma (GBM) and had a re-resection in case of a recurrent tumor following radiochemotherapy and subsequent chemotherapy were included (n = 16). Histological and immunohistochemical stainings were performed at initial diagnosis and at recurrence (n = 96 tissue specimens). Levels of PSMA expression both in endothelial and non-endothelial cells as well as vascular density (CD34) were quantified via immunohistochemistry and changes between initial diagnosis and recurrence were determined. Immunohistochemical findings were correlated with survival and established clinical parameters.Results: PSMA expression was found to be present in all GBM tissue samples at initial diagnosis as well as in all but one case of recurrent tumor samples. The level of PSMA expression in glioblastoma varied inter-individually both in endothelial and non-endothelial cells. Likewise, the temporal evolution of PSMA expression highly varied in between patients. The level of vascular PSMA expression at recurrence and its change between initial diagnosis and recurrence was associated with post recurrence survival time: Patients with high vascular PSMA expression at recurrence as well as patients with increasing PSMA expression throughout the disease course survived shorter than patients with low vascular PSMA expression or decreasing vascular PSMA expression. There was no significant correlation of PSMA expression with MGMT promoter methylation status or Ki-67 labelling index.Conclusion: PSMA is expressed in glioblastoma both at initial diagnosis and at recurrence. High vascular PSMA expression at recurrence seems to be a negative prognostic marker. Thus, PSMA expression in GBM might present a promising target for theranostic approaches in recurrent glioblastoma. Especially PSMA PET imaging and PSMA-directed radioligand therapy warrant further studies in brain tumor patients.

26 July 2019 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
FLFriederike Liesche-Starnecker
Friederike Liesche-Starnecker
VRViktoria Ruf
Viktoria Ruf
SZSaida Zoubaa
Saida Zoubaa
GKGwendolyn Kaletka
Gwendolyn Kaletka
MRMarco Rosati
Marco Rosati
JSJürgen Schlegel
Jürgen Schlegel
After many years of controversy, there is now recent and solid evidence that classical Borna disease virus 1 (BoDV-1) can infect humans. On the basis of six brain autopsies, we provide the first systematic overview on BoDV-1 tissue distribution and the lesion pattern in fatal BoDV-1-induced encephalitis. All brains revealed a non-purulent, lymphocytic sclerosing panencephalomyelitis with detection of BoDV-1-typical eosinophilic, spherical intranuclear Joest–Degen inclusion bodies. While the composition of histopathological changes was constant, the inflammatory distribution pattern varied interindividually, affecting predominantly the basal nuclei in two patients, hippocampus in one patient, whereas two patients showed a more diffuse distribution. By immunohistochemistry and RNA in situ hybridization, BoDV-1 was detected in all examined brain tissue samples. Furthermore, infection of the peripheral nervous system was observed. This study aims at raising awareness to human bornavirus encephalitis as differential diagnosis in lymphocytic sclerosing panencephalomyelitis. A higher attention to human BoDV-1 infection by health professionals may likely increase the detection of more cases and foster a clearer picture of the disease.

1 March 2020 in Translational Oncology
Verified
Journal Article
Open access
WWWei Wu
Wei Wu
YWYang Wu
Yang Wu
KMKaroline Mayer
Karoline Mayer
CRCharlotte von Rosenstiel
Charlotte von Rosenstiel
JSJohannes Schecker
Johannes Schecker
JSJürgen Schlegel
Jürgen Schlegel
Glioblastoma (GBM) is the most malignant primary brain tumor. Relapse occurs regularly, and the clinical behavior seems to be due to a therapy-resistant subpopulation of glioma-initiating cells that belong to the group of cancer stem cells. Aldehyde dehydrogenase (ALDH) has been identified as a marker for this cell population, and we have shown previously that ALDH1A3-positive GBM cells are more resistant against temozolomide (TMZ) treatment. However, it is still unclear how ALDH expression mediates chemoresistance. ALDH1A3 expression was analyzed in 112 specimens from primary and secondary surgical resections of 56 patients with GBM (WHO grade IV). All patients received combined adjuvant radiochemotherapy. For experimental analysis, CRISPR-Cas9-induced knockout cells from three established GBM cell lines (LN229, U87MG, T98G) and two glioma stem-like cell lines were investigated after TMZ treatment. ALDH1A3 knockout cells were more sensitive to TMZ, and oxidative stress seemed to be the molecular process where ALDH1A3 exerts its role in resistance against TMZ. Oxidative stress led to lipid peroxidation, yielding active aldehydes that were detoxified by ALDH enzymatic activity. During the metabolic process, autophagy was induced leading to downregulation of the enzyme, but ALDH1A3 is upregulated to even higher expression levels after finishing the TMZ therapy in vitro. Recurrent GBMs show significantly higher ALDH1A3 expression than the respective samples from the primary tumor, and patients suffering from GBM with high ALDH1A3 expression showed a shorter median survival time (12 months vs 21 months, P < .05). Oxidative stress is an important and clinically relevant component of TMZ-induced therapeutic effects. Cytotoxicity seems to be mediated by aldehydes resulting from lipid peroxidation, and ALDH1A3 is able to reduce the number of toxic aldehydes. Therefore, we present a molecular explanation of the role of ALDH1A3 in therapeutic resistance of human GBM cells.